Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-αvβ6-BP PET/CT in Metastatic NSCLC
NCT05452005Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-αvβ6-BP in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by University of California, Davis. Primary endpoint: [18F]-αvβ6-BP PET/CT imaging compared to immunohistochemistry. Started Sep 2022; status: recruiting.
02
Drugs
18F-αvβ6-BP
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT05452005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452005.